Pharmaceutical patentsOrange BookStructure searching

Pharmaceutical patent search: sources and method

By Ipiry TeamPublished August 24, 20267 min read

Short answer

A pharmaceutical patent search runs through sources that do not exist in other fields. The FDA Orange Book lists patents and exclusivities declared for approved drugs, the Purple Book covers biologics, and chemical structure searching finds compounds that keyword searching never will because Markush claims describe families rather than named molecules. Start from the product where one exists, and from structure where it does not.

A pharmaceutical patent search uses sources that exist nowhere else in patent work.

Regulatory listings come first. The FDA publishes what protects each approved product, which no other field offers.

And chemical claims defeat keyword searching. A Markush claim describes a family of compounds through variable substituents, so a molecule can be covered by a claim that never names it.

Which means the method depends on what you have — a product, a structure, or a therapeutic area.

Starting points

You have	Start with
An approved drug name	Orange Book (small molecules)
An approved biologic	Purple Book
A chemical structure	Structure and substructure searching
A therapeutic area	Classification browsing, then structure
A company	Assignee searching, then verify
A patent number	USPTO records directly

The Orange Book route is the fastest when it applies, because the sponsor has already declared what it believes protects the product.

The Orange Book

Contains	Does not contain
Approved drug products	Process patents
Patents declared by the sponsor	Patents the sponsor chose not to list
Exclusivity periods	Current patent status
Therapeutic equivalence codes	Foreign rights
Application and approval data	Whether a patent was invalidated

Listing decides whether a generic must address the patent in its application, which is what creates the Paragraph IV mechanism and the associated stay.

Process patents cannot be listed. They protect the manufacturing route without shaping the generic approval timeline.

It does not update as patents change. A listed patent may have expired, lapsed, or been narrowed since listing, so every entry needs verifying.

Structure searching

Search type	Finds
Exact structure	The specific compound
Substructure	Claims covering families containing that core
Similarity	Analogues and near neighbours
Markush	Claims whose variable definitions encompass the compound
Reaction	Synthetic routes

Substructure searching is the one that matters. A composition claim covering a core scaffold with defined substituents reaches your compound without naming it, and no text search will surface it.

This generally requires a commercial chemistry database. Free patent tools handle text and classification well and are not built for chemical space.

Classification helps as a supplement. CPC groups pharmaceutical subject matter in ways that narrow the field before structure searching begins.

The patents on one drug

Type	Filed	Expires	Covers
Composition of matter	At discovery	Earliest	The compound itself
Formulation	During development	Later	A specific dosage form
Method of treatment	As indications emerge	Later	The use, per indication
Process	During scale-up	Later	Manufacture
Polymorph / salt form	Later	Later	Specific solid forms
Device (combination products)	Later	Separate clock	Delivery

The composition patent is strongest and expires first, which is why it is normally the one chosen for Patent Term Extension — only one patent per approved product may be extended.

Method patents outlive it and cover less. A generic omitting the patented indication from its label may launch for the other approved uses.

Expiry is not calculable from the patent alone

Input	Source
Twenty years from filing	Front page
Patent Term Adjustment	USPTO — for USPTO delay
Patent Term Extension	USPTO on FDA data — up to 5 years, capped at 14 years from approval
Terminal disclaimer	Front page — caps the term
Maintenance fees	Patent Center — can end it early
Regulatory exclusivity	Orange Book — a separate clock

Effective protection ends at the later of the patent and the exclusivity, and modelling only one is the common error.

Exclusivity	Length
New chemical entity	5 years
New clinical investigation	3 years
Orphan drug	7 years
Biologics	12 years
Paediatric	+6 months to existing periods

See how long do medical patents last.

Maintenance fees still apply

Fee	Due after grant	Large entity
First	3.5 years	$2,150
Second	7.5 years	$4,040
Third	11.5 years	$8,280
Total		$14,470

Pharmaceutical patents frequently grant years before approval, so the first fees fall due before any revenue exists.

A lapsed patent is lapsed regardless of extensions or exclusivity. Verify in Patent Center rather than assuming a listed patent is live — only 41.4% of US utility patents reach full term. See the patent survival curve.

Worked example: searching one product

A small-molecule drug approved in 2023.

Step	Source	Finding
1	Orange Book	6 patents listed, 2 exclusivities
2	Patent Center on each	1 of 6 already lapsed
3	Front pages + PTA	Composition patent filed 2012
4	PTE record	+3.5 years → 2035.5
5	Orange Book exclusivity	NCE to 2028, paediatric to 2028.5
6	Substructure search	2 unlisted third-party patents on the scaffold
7	Espacenet	EP family, SPCs in 4 states

What the Orange Book alone would have missed

Missed	Why it matters
One listed patent had lapsed	Overstates protection
Two third-party patents on the scaffold	Freedom-to-operate risk
European SPC positions	Different expiry per state
Process patents	Never listed

Step six is the one the Orange Book cannot give you. Third-party patents covering the chemical space are not listed anywhere, and finding them requires structure searching.

Protection and freedom to operate are different questions. The Orange Book answers the first; only a structure search addresses the second.

Paragraph IV certifications

Certification	Meaning
Paragraph I	No patent information filed
Paragraph II	The patent has expired
Paragraph III	Will not launch until expiry
Paragraph IV	The patent is invalid or not infringed

Paragraph IV filings trigger litigation. They are the mechanism by which generic entry is contested, and the first successful filer receives 180 days of exclusivity.

Searching Paragraph IV activity tells you which patents are being challenged, which is useful intelligence about which listings the market considers weak.

Biologics differ

	Small molecules	Biologics
Listing	Orange Book	Purple Book
Structure searching	Central	Sequence searching instead
Exclusivity	5 years NCE	12 years
Follow-on entry	Generic	Biosimilar
Post-expiry erosion	Rapid	Slower

Sequence searching replaces structure searching for biologics, and the databases and query types differ accordingly.

Biosimilar entry is slower for manufacturing and substitution reasons independent of the patent position.

Foreign families

Jurisdiction	Extension mechanism
United States	Patent Term Extension
Europe	SPC, per validated state
Japan	Extension system
Korea	Extension system
Most others	None

European patents fragment after grant. Validation creates national rights, and SPCs are granted country by country, so one European family can have different expiry dates across member states.

Build the timeline jurisdiction by jurisdiction. There is no shortcut.

What free tools do well

Tool	Good for
Orange Book / Purple Book	The starting point
Google Patents	Full text, families, translations
USPTO Patent Public Search	Classification, US records
USPTO Patent Center	Status and fee position
Espacenet	Foreign families
Assignment Search	Ownership

Everything except structure searching can be done free. That is worth knowing before commissioning work.

Pharmaceutical patent search: the checklist

Start from the Orange Book for small molecules, the Purple Book for biologics.
Verify every listed patent in Patent Center. Listings do not update.
Do not rely on text searching for chemistry. Markush claims defeat it.
Use substructure searching to find claims covering your compound unnamed.
Expect several patents per product with different scopes and expiry dates.
Remember process patents are never listed.
Model both clocks — patent term and regulatory exclusivity — and take the later.
Check PTA, PTE and terminal disclaimers before calculating any expiry.
Search for third-party patents separately. Protection and FTO are different questions.
Build foreign timelines per jurisdiction. SPCs differ state by state.

Common questions

How do I search for patents on a drug?

Start with the FDA Orange Book, which lists the patents and exclusivities the sponsor declared for each approved product. Then verify each listed patent directly in USPTO records, since the listing does not update as patents expire or are invalidated.

What is the Orange Book?

The FDA's publication of approved drug products with therapeutic equivalence evaluations, which includes patent and exclusivity listings for each product. It is the standard starting point for determining what protects a small-molecule drug.

What is the Purple Book?

The FDA's equivalent listing for biological products, covering licensed biologics and their exclusivity periods. Biologics follow a different regulatory pathway from small molecules, so the two listings are separate.

Why does keyword searching fail for chemistry?

Because patent claims frequently use Markush structures describing whole families of compounds through variable substituents rather than naming molecules. A specific compound can be covered by a claim that never mentions its name anywhere.

What is a Markush claim?

A claim reciting a general structure with defined variable positions, covering every compound falling within those definitions. One claim can cover an enormous number of specific molecules, which is why structure searching rather than name searching is required.

Which patents cover a drug?

Typically several with different scopes and expiry dates — composition of matter on the compound, formulation patents, method-of-treatment patents for each indication, and process patents on manufacture. The composition patent is usually the strongest and expires first.

Are process patents listed in the Orange Book?

No. Manufacturing process patents cannot be listed, which means they protect against practising the process without shaping the generic approval timeline in the way listed patents do.

How do I find foreign equivalents?

Espacenet gives family-level views showing counterparts across jurisdictions. Rights are national, so protection in one country says nothing about another, and expiry dates diverge because extension mechanisms differ.

What is a Supplementary Protection Certificate?

The European mechanism roughly corresponding to US Patent Term Extension, granted country by country after national validation. Terms and calculations differ from the US system, so a global timeline has to be built jurisdiction by jurisdiction.

Does the Orange Book tell me when protection ends?

It gives the declared patents and exclusivities, which is the starting point rather than the answer. Each patent's actual status, term adjustment, extension and maintenance fee position must be checked in USPTO records.

Do I need a commercial chemistry database?

For serious structure searching, yes. Free tools handle text and classification searching well, but substructure and similarity searching over chemical space generally requires a commercial database built for it.

How does this differ from an ordinary patent search?

The sources, the claim types and the timelines. Regulatory listings do not exist in other fields, Markush claims make text searching unreliable, and term extensions and exclusivity periods mean expiry is not calculable from the patent alone.

Patents on pharmaceutical drugs and what they cost

Why patented drugs cost what they do, how patents and regulatory exclusivity interact, when generics can enter, and what actually determines the date prices fall.

Pharmaceutical patents: exclusivity, generics and the cliff

How drug patents work — the types filed around a single product, the Orange Book, Paragraph IV challenges, regulatory exclusivity running alongside patent term, and what happens at the cliff.

How long do medical patents last?

Why medical patents last longer than the twenty-year term suggests — Patent Term Extension, regulatory exclusivity, and why drugs and devices give different answers.

What is your patent worth?

Free AI valuation in 60 seconds, benchmarked against 652,000 KPSS patent value records and the Ipiry Patent Survival Curve.

Value My Patent Free →Takes 60 seconds. No credit card required.